Indaptus Therapeutics, Inc. is excited to announce a successful funding round that has secured $2,300,000 in new capital. This significant investment underscores the confidence that investors have in our innovative approach and vision to cure disease. With our commitment to revolutionizing the treatment of cancer and certain infectious diseases, the infusion of funds will accelerate our groundbreaking research and development efforts. At the core of our mission is the unique ability to harness both innate and adaptive immune responses. Our proprietary platform, which is inspired by the observation that tumor regression can occasionally coincide with bacterial infections, leverages bacteria’s natural ability to stimulate a comprehensive immune response. We have refined this process to safely activate both immune pathways, paving the way for a broad and potent anti-tumor and anti-viral activity.
The secured funds will empower Indaptus Therapeutics to further develop, refine, and validate our pipeline of proprietary, attenuated, and killed non-pathogenic gram-negative bacterial candidates. This technology is engineered to be widely accessible, offering hope for a revolutionary new category of immunotherapeutics with extensive applications in oncology and infectious disease management. By advancing our understanding of the balance and ratios of activating signals needed to elicit a full-scale immune response, we are poised to transform current treatment paradigms. As we move forward with this investment, we remain steadfast in our goal: to cure disease through innovative science that brings transformative therapies to patients in need. This funding milestone marks an important step in our journey to redefine the landscape of immunotherapy and deliver on our promise to impact patient lives on a global scale.
